Peptide

Semax

Semax (Met-Glu-His-Phe-Pro-Gly-Pro)

A Russian synthetic ACTH(4-10) analog used clinically for stroke recovery and ADHD. Raises BDNF and dopamine tone in prefrontal cortex. Approved in Russia, unlisted elsewhere.

Editor approved

Summary What is Semax, and does it really help the brain? Show / hide ↓

Semax is a laboratory-made peptide, meaning a small chain of amino acids, used as a prescription medicine in Russia. It is usually sprayed into the nose at 200 to 600 micrograms per day and is used there for stroke recovery and ADHD in children. Russian reports describe better attention and recovery, but these findings have not been confirmed in completed Western trials. Animal studies suggest Semax may raise BDNF, a protein involved in brain growth and repair, and affect dopamine, a chemical linked to attention and motivation. Three decades of Russian use have not shown major safety problems, but long-term effects and benefits for general focus or mood remain uncertain.

What this means for you: Semax has substantial use in Russia, but reliable independent evidence is still limited. There is not enough evidence to buy it for general focus, motivation, or mood.

early evidence

Research snapshot No human clinical trials in indexed journals. Russian cognitive peptide.

Updated 2026-08-11

Semax is a Russian-developed peptide derived from ACTH that is approved in Russia for cognitive and stroke recovery indications. Russian-language clinical studies exist but are not widely replicated in Western journals. It is not approved by the FDA or EMA. Its cognitive enhancement claims need independent confirmation.

Evidence tierTier 3, Mixed human evidence, mechanism plausible

Typical doseIntranasal, 200 to 600 mcg per day, split across two to three administrations, mornings. Available as 0.1 percent standard or 1 percent (Semax Enhanced).

SafetyReassuring Russian post-marketing safety data. Transient nasal irritation and rare headache reported. Sleep disruption if dosed late in the day. Long-term effects on baseline dopaminergic tone with chronic use are not well studied.

Categorynootropic peptide (approved in Russia)

Last verified2026-08-05

Semax is an outlier: a peptide with real prescription-medicine status in a G20 country, decades of clinical use, and yet essentially zero regulatory footprint outside Russia. This creates a strange evidence pattern where the peptide has more real human use than most Western-developed peptides but almost none of that use has been captured in indexed English-language trials.

The Russian evidence base includes reported efficacy in ischemic stroke recovery (accelerated motor and cognitive rehabilitation over 10 to 20 day inpatient courses), attention deficit hyperactivity disorder in children (improved attention scores over 30 day courses), optic nerve atrophy, and general anxiety and stress conditions. Standard dosing is intranasal, 200 to 600 mcg per day, split across two to three administrations.

Mechanistically, Semax raises BDNF (brain-derived neurotrophic factor) expression by roughly 40 to 60 percent in prefrontal cortex in rat studies, upregulates NGF, and increases dopaminergic tone particularly at D1 receptors in prefrontal regions. This maps to the receptor system implicated in ADHD, which is why Russian pediatric neurology has used Semax for ADHD symptoms for over two decades. It also raises endogenous opioid tone modestly, which contributes to anxiolytic effects.

Inside the biohacker community, Semax is popular for focus, motivation, and mood support, often paired with Selank (an anxiolytic peptide from the same institute). Users report increased drive and cognitive stamina without the crash of classical stimulants. Anti-doping bodies including WADA have banned Semax in competitive sport due to its neuroactive effects.

Safety in Russian post-marketing surveillance is reassuring. No major toxicity signals have emerged from clinical use spanning three decades. Reported side effects are mild: transient nasal irritation, rare headache, occasional insomnia when dosed late. Long-term effects on natural dopaminergic tone with chronic use have not been formally studied.

Our position: Semax sits at Tier 3 for the specific Russian-approved indications (stroke recovery, ADHD in children), based on Russian clinical use plus a modest independent literature. Tier 4 for the community uses (general focus, motivation, mood support), based on solid mechanism and user experience but no completed Western RCT.

2026 evidence and regulatory refresh

Semax is an approved Russian nasal-spray drug for stroke and cognitive indications with real, if methodologically dated, human trial data, and it received one of the strongest PCAC votes in July 2026.

Verified 2026-08-06. We update this section as PCAC decisions, ClinicalTrials.gov entries, and new peer-reviewed studies land.

FDA / PCAC (July 2026)

Reviewed July 23-24, 2026. The PCAC voted 8-5-1 to recommend Semax for the 503A Bulks List, one of the higher yes-vote totals among the seven reviewed peptides, against FDA staff's own briefing document recommending against all seven (https://www.fda.gov/media/193343/download). The vote is advisory and non-binding (https://validusbio.com/learn/pcac-2026-peptide-vote-results/).

US status

Not FDA approved in the US for any indication; not currently on the 503A Bulks List. Removed from FDA's Category 2 list in April 2026 after its nomination was withdrawn.

EU status

Not authorised for human use in EU as of 2026; approved as a prescription nasal-spray drug in Russia, where it is registered and clinically used but has not gone through EMA review.

Human RCT base

peer-reviewed randomised trials

Largest human study

n = 110

Clinical trial in ischemic stroke patients divided into early and late rehabilitation subgroups with semax and non-semax arms; randomization and blinding status not stated in the available record. Semax administration increased plasma BDNF levels regardless of rehabilitation timing, with associated improvements in motor performance and Barthel index functional recovery scores over 5 months of follow-up. source

Best-supported claim

Semax has been used clinically in Russia for decades as a prescription nasal spray, and a 110-patient stroke-rehabilitation study found that two 10-day courses at 6000 mcg/day raised plasma BDNF and correlated with better motor and functional recovery scores compared to patients not receiving semax (https://pubmed.ncbi.nlm.nih.gov/29798983/). This is real human outcome data, but the study's exact randomization and blinding methodology is not clearly documented in available English-language sources, and it has not been replicated in a Western, peer-reviewed, pre-registered RCT.

Not supported by the evidence base

US and European nootropic vendors market Semax as a cognitive-enhancement drug for healthy adults, extrapolating from stroke-rehabilitation data in brain-injured patients (https://thepeptidecatalog.com/articles/semax-benefits). No RCT has tested Semax for cognitive enhancement, memory, or focus in healthy people. Claims of "BDNF-boosting" nootropic effects in the general population are lifted from a single stroke-patient population and applied without evidence to an entirely different use case.

Typical usage

6000 mcg/day intranasal, given as two 10-day courses with a 20-day interval between courses, per the published Russian stroke-rehabilitation protocol; wellness and nootropic users commonly self-administer 200-600 mcg/day intranasally with no clinical validation for that dose or population.

Safety

The 110-patient stroke study reported no major safety signal at the studied dose over 5 months of follow-up, but detailed adverse-event reporting is not available in English-language summaries (https://pubmed.ncbi.nlm.nih.gov/29798983/). FDA's July 2026 briefing document lists Semax among substances with insufficient characterization and unassessed immunogenicity risk for compounded use (https://www.fda.gov/media/193343/download). There is no safety data in pregnant people, children, or people with seizure disorders; anyone on other neuroactive or ACTH-pathway drugs should be cautious given Semax's origin as an ACTH(4-10) analog.

Interactions worth flagging

No formal drug-interaction studies exist outside Russian clinical use
Theoretical interaction with other nootropic or ACTH-pathway compounds (e.g., Selank) commonly stacked with Semax
Unknown interaction with antidepressants or anticonvulsants given its neuroactive mechanism

Three recent studies to know

The efficacy of semax in the treatment of patients at different stages of rehabilitation after ischemic stroke

Zhurnal Nevrologii i Psikhiatrii (Russian neurology journal) 2018 · n = 110

Semax increased plasma BDNF and was associated with better motor and Barthel index recovery in ischemic stroke patients regardless of rehabilitation timing.
Read study →
What the FDA's July 2026 PCAC Peptide Review Decided

Validus Bio (regulatory analysis) 2026 · n = n/a

PCAC voted 8-5-1 to recommend Semax for the 503A Bulks List against FDA staff's own negative position; non-binding.
Read study →
FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting

FDA (regulatory briefing document) 2026 · n = n/a

FDA staff recommended against adding Semax to the 503A Bulks List, citing insufficient human safety and characterization data.
Read study →